Release date: 2026-07-17 16:57:55 Recommended: 6
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was established in Vientiane, the capital of Laos, in 2020 and has been in operation for over five years. Its parent company can be traced back to Lucius Pharmaceutical Co., Ltd., founded in Hyderabad, India, in 2014.
Lucius Pharmaceutical is a legal pharmaceutical enterprise approved by the Lao government. The company is located in Thongmang Village, Xaythani District, Vientiane City, with a factory covering an area of approximately 210,000 square meters. It has built the Asia Pacific No.1 Smart Factory and introduced pharmaceutical equipment from China, the United States, Germany, and other countries. The company has obtained GMP (Good Manufacturing Practice) certification issued by the Lao Ministry of Health.
As of June 2024, Lucius Pharmaceutical has more than 200 generic drug varieties. Its products cover multiple therapeutic areas, including anti-tumor drugs, cardiovascular drugs, hematology drugs, diabetes drugs, dermatology drugs, men's health drugs, and anti-aging drugs.
In the field of anti-cancer drugs, the company has obtained marketing approvals for 54 anti-cancer drugs. Representative products include Sotorasib, Osimertinib, Cabozantinib, Larotrectinib, Lorlatinib, Ivosidenib, Gilteritinib, and many other targeted therapeutic drugs. In addition, the company has launched global first-generic products such as Revumenib.
Lucius Pharmaceutical has an annual generic drug production capacity exceeding 1.5 billion tablets. The company strictly organizes production in accordance with GMP standards and has established a full-process quality control system covering raw material procurement, production processes, and finished product inspection.
In October 2023, the World Health Organization (WHO) conducted a comprehensive assessment of Lucius Pharmaceutical's factory and confirmed that its facility fully complies with WHO standards. The company's production environment simultaneously meets GMP standards of Laos, the European Union, the United States, and China.
Lucius Pharmaceutical's business has expanded to multiple countries and regions, including Thailand, Indonesia, Cambodia, Vietnam, the Philippines, Singapore, Malaysia, Turkey, Japan, and China. The company's products are mainly sold to markets in Southeast Asia, the Middle East, Eastern Europe, and Africa.
For patients with medication needs, it is recommended to obtain drugs through formal channels under the professional guidance of a licensed physician or pharmacist.
Lucius Pharmaceutical is one of the representative generic drug enterprises in L···【more】
Recommended:7Release date: 2026-07-17
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosiv···【more】
Recommended:20Release date: 2026-07-16
In recent years, Laos generic drugs have gradually come into view of oncology an···【more】
Recommended:32Release date: 2026-07-15
Regulatory System: From "One Ministry, One Department" to Legal Amendm···【more】
Recommended:48Release date: 2026-07-14
Overview of Lao generic drug industryThe Lao generic drug industry started late ···【more】
Recommended:74Release date: 2026-07-09
Laos's pharmaceutical industry started late and remains relatively small in ···【more】
Recommended:80Release date: 2026-07-08
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently mad···【more】
Recommended:782Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest incr···【more】
Recommended:741Release date: 2024-07-09
Lao PDR: Filgotinib Has Been LaunchedBefore initiating filgotinib treatment, str···【more】
Recommended:49Release date: 2026-07-13
Lucius Pharmaceuticals' Pirtobrutinib Has Been LaunchedPirtobrutinib is an o···【more】
Recommended:78Release date: 2026-07-10
Lucius Pharmaceuticals (Lao) Co., Ltd. has launched a generic version of elagoli···【more】
Recommended:82Release date: 2026-07-06
Contraindications for Bempedoic Acid (Nilemdo)Bempedoic acid (Nilemdo) is strict···【more】
Recommended:97Release date: 2026-07-03
MONDAY, June 15, 2026 — A study published online June 8 in Nature Medicine has f···【more】
Recommended:123Release date: 2026-06-24
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durv···【more】
Recommended:233Release date: 2026-06-01